Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aldesleukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aldesleukin overview
Aldesleukin (Proleukin) is an immunoregulatory and antineoplastic product. It is a lymphokine that is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. It is formulated as lyophilized powder for solution for subcutaneous, intravenous administration. Proleukin is indicated for the treatment of adults with metastatic kidney cancer (renal cell carcinoma). Further, the drug is indicated for the prevention of metastatic melanoma for adults patients.
Aldesleukin is under development for the treatment of graft versus host disease and common variable immunodeficiency. It was also under development for the treatment of HIV/AIDS, acute myelocytic leukemia, B-cell non-Hodgkin lymphomas including indolent lymphoma, mantle cell lymphoma, follicular lymphoma, amyotrophic lateral sclerosis.
Iovance Biotherapeutics overview
Iovance Biotherapeutics (Iovance) is a biotechnology company that focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include lifileucel is an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer; and LN-145 for the treatment of head and neck cancer. The company also focuses on investigating TIL therapy for treatment of a various types of cancer. It has Iovance Cell Therapy Center (iCTC) in Philadelphia for the manufacture of the tumor infiltrating lymphocytes (TIL). The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
For a complete picture of Aldesleukin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
